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Blood 2005;106:1901–10.Letters to the Editorardiac Resynchronization
herapy and Atrial
achyarrhythmias: A Question
till Searching for an Answer
t is with great interest that we read the article in the September
5, 2007, issue of the Journal by Yannopoulos et al. (1). The
nding of reduced atrial tachyarrhythmia (AT) burden after
ardiac resynchronization therapy (CRT) implantation is indeed
n intriguing finding that is pleasing from a pathophysiological
nd clinical perspective. However, in reviewing the literature on
his topic, we feel that a contribution from our laboratory has been
eglected. We performed a retrospective analysis of 27 patients
ho failed CRT implantation at our institution and did not go on
o have an epicardial left ventricular (LV) lead surgically implanted
2). These patients were then matched, by gender, age, heart
ailure etiology, and history of atrial fibrillation (AF) with 2 CRT
atients, 1 responder, and 1 nonresponder. We found no difference
n AF burden between the CRT and non-CRT cohorts, using
evice-based diagnostics as the means of detecting ATs, although
RT patients with no history of AF did have a longer time to their
rst AF event. Our findings contradict those of the present study
nd are in agreement with those of Fung et al. (3).
The present study, while well performed, has certain flaws
orth mention. First, the exact method of determining the number
f AT episodes was not described. For example, would 2 4-s
ode-switch episodes occurring within 1 min be classified as
eparate events? It is more likely that this reflects a single AT event
hat is undersensed by the device, which then records separate
vents. For this reason, quantification of AT burden by mode-
witching episodes may be inaccurate. A second weakness is theates, and the longest and shortest AT episodes are less clinically
elevant than the total AT duration burden, especially given the
ropensity for devices to undersense AT. Thromboembolic risk
nd hemodynamic stress would seem to depend more upon
uration and total burden of AT, not the number of episodes. The
ercentage of AT episodes with saved electrograms is also an
mportant piece of omitted data. The atrial rates during AT
pisodes, in particular, are largely irrelevant. Whereas AF should
egister as a faster rate than an atrial tachycardia or flutter,
ndersensing of fibrillatory waves by the device (as graphically
llustrated in the printed electrograms) may paradoxically create
he opposite effect. Furthermore, ventricular response during atrial
achycardia and flutter is oftentimes more difficult to control than
F, making AT episodes with slower atrial rates potentially more
linically symptomatic. Finally, it would appear that AT episodes
efore CRT were quantified strictly from device counters without
eview, whereas episodes after CRT, when electrograms were
vailable, were reviewed. This may have led to overreporting of
vents before CRT, again, because of the propensity of devices to
ndersense ATs.
We do agree with the authors that studies examining AT
urden without implanted devices present in both groups (e.g., the
ARE-HF [Cardiac Resynchronization Heart Failure Study]
nalysis in patients with and without CRT [4]) are of little benefit.
etermining AF burden by random electrocardiograms has been
emonstrated to be of little clinical import, and Yannopoulos et al.
1) rightly emphasize that the presence of a device in only 1 group
ill invariably lead to inequities in detection.
Currently, the role of CRT in reducing atrial arrhythmias
emains speculative, as the only data come from retrospective or
ncontrolled studies. Unfortunately, in the present clinical climate,
he prospect of a prospective study examining this question is grim,
s are any studies with a true control group examining the effects
f CRT in selected populations. This is unfortunate, in that AT
urden may provide important objective evidence for a direct effect
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February 12, 2008:674–7f CRT upon improving left-sided filling pressures and cardiac
emodynamics, which, after all, should be the mechanism by
hich pulmonary congestion, dyspnea on exertion, and fatigue are
lleviated by CRT.
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eply
rs. Adelstein and Saba raise a number of criticisms regarding our
ecent publication in which we observed that the number of atrial
achyarrhythmia (AT) events in heart failure patients diminished
fter conventional dual-chamber pacemakers or defibrillators were
upgraded” to cardiac resynchronization (CRT) systems (1). We
ave endeavored to address their comments.
First, Drs. Adelstein and Saba indicate disappointment in our
ot citing their publication (2). This omission was not intentional;
ur manuscript was accepted on April 24, 2007, and was at the
ublishers when theirs was printed (July 15, 2007). Thus, publi-
ation schedules crossed. Second, they criticize how we counted
T events (i.e., mode switch counts with electrogram review when
vailable) without having documentation of all events (a limitation
oted by us). They are concerned that transient undersensing may
esult in our having counted “multiple” apparent individual AT
pisodes (instead of 1 ongoing episode), thereby overestimating
T frequency; further, they suggest that, absent electrograms, we
ould not substantiate that ATs were present. With regard to the
ormer, we believe that the device algorithms used and our
easurement techniques minimized the “overcounting” problem.
owever, if, as they contend, it was impossible to eliminate all
overcounting,” our “upgrade study model,” with each patient
eing his/her own control, inherently protected against an impor-
ant counting bias; error susceptibility would be similar before and
fter CRT upgrade. In this regard, our study design is more robust
han their case-control methodology (2). With regard to the
econd aspect of their documentation criticism, one might be led to
ssume that in their report Drs. Adelstein and Saba either vetted
very mode switch event with electrograms or censored those thatould not be vetted. However, neither seems to be true. In fact,
lthough they indicate that “electrographic data” were available in
8% of patients, they do not state unequivocally that all events
ere documented by electrograms. The probability of complete
etting is unlikely unless either data downloads were very frequent
r undocumented events were censored (which could result in
ndercounting). In fact, they admit that absent electrocardio-
raphic data “. . . episode counters and mode switch dura-
ions . . . were assumed to be correct.” In effect, their study is
ubject to the same criticism they level at us, while lacking the
nternal controls offered by our study design. Third, Drs. Adelstein
nd Saba criticized our focusing on AT events and AT rate as
linical end points, believing that AT burden is more important. In
his regard, we believe that episode duration is an important
eterminant of thromboembolic risk, but otherwise our opinions
re similar (3). Indeed, whereas the number of AT events and
urations that we provided may not be a precise “burden” measure,
hey provide a “burden” surrogate. Finally, the Pittsburgh research-
rs point out that, unlike both Fung et al. (4) and our study (1),
hey did not observe a significant CRT benefit. However, that may
ave been due to limitations of their study design. In fact, their
gures suggest that CRT patients did better than control patients;
pecifically, CRT was associated with a trend toward greater
T-free proportion at any given time. Potentially, had their
opulation been larger, or had they used a more robust study
odel (such as our “upgrade” approach), the trend toward benefit
ay have been significant.
Differences aside, we appreciate the interest shown by Drs.
delstein and Saba in our study and look forward to their
ontinuing to contribute to the better understanding of CRT in
linical care.
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